LRRC75A-AS1は,miR489-3p/ARD1を調節するCeRNAとして機能することで,乳がん細胞の増殖と侵入を促進する
Chunjiao Yu1,2, Zhiyuan Wang3, Xi Zhang4
1Institute of Biomedical Engineering, Kunming Medical University, 1168 West Chunrong Road, Chenggong District, Kunming, 650500, Yunnan, P.R. China.
Scientific reports
|August 26, 2025
まとめ
長い非コーディングRNALRRC75A-AS1は,ARD1を上調するmiR-489-3pをスポンジ化することによって,乳がんを促進する. このLRRC75A- AS1/ miR-489- 3p/ ARD1経路は癌の進行を促し,潜在的な治療目標を提供します.
科学分野:
- 分子生物学
- 腫瘍学
- 遺伝学
背景:
- 乳がん (BC) の進行には複雑な分子メカニズムが含まれています.
- 新規の調節経路を特定することは 効果的な治療戦略に不可欠です
研究 の 目的:
- 乳がんの進行におけるARD1の分子メカニズムを解明する.
- ARD1発現とBC悪性腫瘍の制御におけるLRRC75A-AS1/miR-489-3p軸の役割を調査する.
主な方法:
- 遺伝子発現分析のための定量逆転写ポリメラーゼ連鎖反応 (RT-PCR)
- 二重ルシフェラーゼレポーターアッセイ,RNA免疫プレシピテーション (RIP),RNAプルダウンアッセイで分子相互作用を検証する.
- 機能的役割を評価するために,体内試験 (コロニー形成,トランスウェル,ウエスタンブロット) と体内腫瘍異種移植実験を裸のマウスで行いました.
主要な成果:
- ARD1はBC細胞の増殖,侵入,および上皮からメゼンキマへの移行 (EMT) を促進する.
- LRRC75A- AS1は,競合する内生RNA (ceRNA) として miR-489- 3pをスポンジングし,ARD1のアップレギュレーションにつながります.
- LRRC75A- AS1を静止すると,腫瘍の成長がin vivoで抑制され,BCの進行におけるLRRC75A- AS1/ miR- 489-3p/ ARD1軸の役割が確認された.
結論:
- LRRC75A- AS1は,miR- 489-3pをスポンジ化し,ARD1をアップレギュレーションすることによって,乳がんの進行を促進します.
- LRRC75A-AS1/miR-489-3p/ARD1 ceRNA軸は,BCにおける新しい調節経路である.
- この軸は乳がん治療の有望な治療目標です
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K


